Ascendis Pharma A/S (NASDAQ:ASND) – Analysts at Wedbush dropped their FY2017 earnings estimates for Ascendis Pharma A/S in a report issued on Wednesday. Wedbush analyst L. Moussatos now expects that the biotechnology company will post earnings of ($4.25) per share for the year, down from their previous forecast of ($3.58). Wedbush has a “Outperform” rating and a $10.71 price target on the stock. Wedbush also issued estimates for Ascendis Pharma A/S’s Q4 2017 earnings at ($1.00) EPS, Q1 2018 earnings at ($1.01) EPS, Q2 2018 earnings at ($1.03) EPS, Q3 2018 earnings at ($1.05) EPS, Q4 2018 earnings at ($1.07) EPS, FY2018 earnings at ($4.17) EPS, FY2019 earnings at ($5.13) EPS, FY2020 earnings at ($4.52) EPS and FY2021 earnings at ($0.37) EPS.
A number of other analysts also recently commented on the company. Bank of America dropped their price objective on Ascendis Pharma A/S from $46.00 to $43.00 and set a “buy” rating on the stock in a research note on Friday, November 17th. Wells Fargo & Company reissued a “buy” rating and issued a $51.00 price objective on shares of Ascendis Pharma A/S in a research note on Friday, September 22nd. Credit Suisse Group reissued an “outperform” rating and issued a $50.00 price objective (up previously from $30.00) on shares of Ascendis Pharma A/S in a research note on Friday, September 22nd. Leerink Swann reissued a “hold” rating and issued a $28.00 price objective on shares of Ascendis Pharma A/S in a research note on Friday, September 1st. Finally, Zacks Investment Research downgraded Ascendis Pharma A/S from a “hold” rating to a “sell” rating in a research note on Wednesday, August 23rd. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $36.45.
Shares of Ascendis Pharma A/S (NASDAQ:ASND) opened at $36.61 on Monday. Ascendis Pharma A/S has a 12 month low of $19.21 and a 12 month high of $42.00.
Several hedge funds and other institutional investors have recently modified their holdings of the stock. Bank of Montreal Can grew its holdings in shares of Ascendis Pharma A/S by 127.4% during the second quarter. Bank of Montreal Can now owns 4,535 shares of the biotechnology company’s stock valued at $126,000 after buying an additional 2,541 shares in the last quarter. Bank of America Corp DE grew its holdings in shares of Ascendis Pharma A/S by 23.6% during the first quarter. Bank of America Corp DE now owns 5,345 shares of the biotechnology company’s stock valued at $150,000 after buying an additional 1,020 shares in the last quarter. Victory Capital Management Inc. purchased a new position in shares of Ascendis Pharma A/S during the third quarter valued at $194,000. Deschutes Portfolio Strategy LLC purchased a new position in Ascendis Pharma A/S in the second quarter valued at about $238,000. Finally, Aperio Group LLC purchased a new position in Ascendis Pharma A/S in the third quarter valued at about $241,000. Institutional investors and hedge funds own 78.93% of the company’s stock.
WARNING: This news story was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of US & international trademark and copyright legislation. The original version of this news story can be read at https://www.dispatchtribunal.com/2017/12/05/wedbush-weighs-in-on-ascendis-pharma-ass-fy2017-earnings-asnd.html.
Ascendis Pharma A/S Company Profile
Ascendis Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in applying its TransCon technology to develop sustained release prodrug therapies with several product candidates in clinical and preclinical development. The Company is developing its product candidate, TransCon human growth hormone (TransCon hGH) for once-weekly administration to treat growth hormone deficiency (GHD) and other indications.
Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.